A new trading day began on Monday, with EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock price down -6.27% from the previous day of trading, before settling in for the closing price of $7.65. EYPT’s price has ranged from $6.90 to $30.99 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 24.90% over the last five years. Meanwhile, its annual earnings per share averaged -19.37%. With a float of $61.83 million, this company’s outstanding shares have now reached $68.25 million.
The firm has a total of 121 workers. Let’s measure their productivity. In terms of profitability, gross margin is 91.48%, operating margin of -255.88%, and the pretax margin is -226.38%.
EyePoint Pharmaceuticals Inc (EYPT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of EyePoint Pharmaceuticals Inc is 9.41%, while institutional ownership is 82.30%. The most recent insider transaction that took place on Oct 23 ’24, was worth 673,355. Before that another transaction happened on Oct 14 ’24, when Company’s Former Director proposed sale 36,975 for $8.92, making the entire transaction worth $329,817.
EyePoint Pharmaceuticals Inc (EYPT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.55 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -19.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.76% during the next five years compared to 29.57% growth over the previous five years of trading.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Trading Performance Indicators
Here are EyePoint Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -2.51 in one year’s time.
Technical Analysis of EyePoint Pharmaceuticals Inc (EYPT)
Analysing the last 5-days average volume posted by the [EyePoint Pharmaceuticals Inc, EYPT], we can find that recorded value of 0.56 million was lower than the volume posted last year of 0.72 million. As of the previous 9 days, the stock’s Stochastic %D was 22.01%. Additionally, its Average True Range was 0.62.
During the past 100 days, EyePoint Pharmaceuticals Inc’s (EYPT) raw stochastic average was set at 3.81%, which indicates a significant increase from 2.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.67% in the past 14 days, which was higher than the 86.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.11, while its 200-day Moving Average is $9.76. Now, the first resistance to watch is $7.43. This is followed by the second major resistance level at $7.70. The third major resistance level sits at $7.85. If the price goes on to break the first support level at $7.01, it is likely to go to the next support level at $6.86. Should the price break the second support level, the third support level stands at $6.59.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Key Stats
With a market capitalization of 489.36 million, the company has a total of 68,251K Shares Outstanding. Currently, annual sales are 46,020 K while annual income is -70,800 K. The company’s previous quarter sales were 10,520 K while its latest quarter income was -29,360 K.
